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Abstract
B cells develop high affinity receptors during the course of affinity maturation, a cyclic process
of mutation and selection. At the end of affinity maturation, a number of cells sharing the same
ancestor (i.e. in the same “clonal family”) are released from the germinal center; their amino acid
frequency profile reflects the allowed and disallowed substitutions at each position. These clonal-
family-specific frequency profiles, called “substitution profiles”, are useful for studying the course of
affinity maturation as well as for antibody engineering purposes. However, most often only a single
sequence is recovered from each clonal family in a sequencing experiment, making it impossible to
construct a clonal-family-specific substitution profile. Given the public release of many high-quality
large B cell receptor datasets, one may ask whether it is possible to use such data in a prediction model
for clonal-family-specific substitution profiles. In this paper, we present the method “Substitution
Profiles Using Related Families” (SPURF), a penalized tensor regression framework that integrates
information from a rich assemblage of datasets to predict the clonal-family-specific substitution profile
for any single input sequence. Using this framework, we show that substitution profiles from similar
clonal families can be leveraged together with simulated substitution profiles and germline gene
sequence information to improve prediction. We fit this model on a large public dataset and validate
the robustness of our approach on an external dataset. Furthermore, we provide a command-line tool
in an open-source software package (https://github.com/krdav/SPURF) implementing these ideas
and providing easy prediction using our pre-fit models.
Introduction
In the therapeutic antibody discovery and engineering field, researchers commonly isolate antibodies from
animal or human immunizations and screen for functional properties such as binding to a target protein.
Following the initial screening process, a small number of well-behaving antibodies (hits) are isolated
for more rigorous examination of their biophysical properties in order to determine their potential as a
therapeutic. After this stage, only a few final antibodies remain as lead candidates. However, even these
carefully selected antibodies often have immunogenic peptides or other undesirable properties such as
poor thermo/chemical stability and aggregation tendencies. To address these problems, the art of anti-
body engineering has emerged (Igawa et al., 2011), with numerous rational design strategies developed
to mitigate aggregation. Researchers have removed hydrophobic surface patches to avoid aggregation
(Clark et al., 2014; Casaz et al., 2014; Courtois et al., 2016; Geoghegan et al., 2016), “deimmunized”
complementarity-determining regions by screening immunogenic peptides and mutating positions detri-
mental for peptide MHCII binding (Harding et al., 2010), and improved thermostability through stable
framework grafting (McConnell et al., 2014) and targeted mutagenesis using predictions from propri-
etary structure/sequence analysis software (Seeliger et al., 2015). Although referred to as “rational”,
the choice of which amino acid to use for a site-directed mutation is often made using 1) the germline
as a reference, 2) biochemical similarity between amino acids, or 3) the highest probability amino acid
from a generic substitution matrix (e.g. BLOSUM) (Henikoff and Henikoff, 1992). However, neither of
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these three methods are explicitly designed to conserve antibody functionality (i.e. binding to the same
epitope with the same kinetics), so mutations are likely to have negative side effects on affinity. These
considerations motivate a prediction problem: given a B cell receptor (BCR) sequence, which positions
can be modified, and to which amino acids, without drastically changing the binding properties of the
resulting BCR?
An immunization-derived antibody has already implicitly explored the mutational space through the
population of B cells from which it derives, referred to as its clonal family (CF). The members of a CF
are raised during affinity maturation in a germinal center and carry fitness information about the effect
of amino acid substitutions. A profile of the observed substitutions aggregated over all the B cells in a
CF reveals which sites are more conserved, which sites can be more freely edited, and which amino acids
can be used for replacements. However, we generally do not sequence all the B cells that are released
from a germinal center so the information to make such a substitution profile is lost. Thus, we can
formulate a more specific version of our prediction problem: given bulk BCR data and a single input
sequence, can we infer the most likely per-site substitutions that are allowed in its true germinal center
lineage?
We begin by reviewing the natural mutation and selection process of germinal center affinity matura-
tion. The Darwinian selection undertaken inside a germinal center is driven by B cells’ ability to bind the
antigen through the membrane-embedded BCR. The population of B cells in a germinal center is under
stringent selection while being highly mutated, driving the cell population towards higher and higher
affinity until the germinal center is dissolved. Each germinal center is seeded by around one hundred
naive B cells, but eventually internal competition makes one or a few of these lineages take over the
whole germinal center (Tas et al., 2016). Although B cells in the germinal center reaction experience
an extraordinarily high mutation rate (106 fold higher than the regular somatic mutation rate (Victora
and Nussenzweig, 2012)), they rarely harbor more than 15% mutations at the DNA level (Briggs et al.,
2017). However, since they must maintain some degree of antigen specificity to survive during the course
of the germinal center reaction, lineages evolve in small incremental steps (Kepler et al., 2014; Kuraoka
et al., 2016) and therefore, even lineages that drift far away from their naive B cell ancestor most likely
maintain the same epitope specificity throughout the germinal center reaction (Schmidt et al., 2013).
We can describe the combination of germinal center mutation and selection dynamics by computing
per-site amino acid frequency vectors from observed BCR sequence data. We follow previous authors in
calling site-specific amino acid probability vectors “substitution profiles”, where each vector in a profile
stores the probabilities of observing the 20 different amino acids at a given site (Sheng et al., 2017). We
use the concept of a clonal family, defined by a shared naive DNA sequence, to segment BCR sequences
into evolutionarily-related groups (Ralph and Matsen IV, 2016b). CF inference is highly informed by
nucleotide sequences and therefore performed using DNA sequences. This makes DNA-level information
necessary even though germinal center selection operates at the protein level and synonymous codons
do not possess any fitness advantages (modulo transcription rate differences and codon bias, which we
follow many others in ignoring here). The per-site amino acid frequency vectors described above form
the substitution profile estimates; the substitution profile estimates converge to the true substitution
profiles as the number of sequences sampled from the same CF tends to infinity.
Most CFs do not contain enough sequences in order to get a detailed substitution profile estimate.
Indeed, most CFs in repertoire sequencing (Rep-Seq) samples have few members and a large fraction
are singletons due to the exponential nature of the CF size distribution (Ralph and Matsen IV, 2016b).
Additionally, many antibody screening methods are not geared towards whole repertoire sequencing.
One may wish, then, to enhance the substitution profile estimates for data-sparse CFs with substitution
profile information from similar CFs.
In this paper, we present “Substitution Profiles Using Related Families” (SPURF), a penalized tensor
regression framework that integrates multiple sources of information to predict the CF-specific amino
acid frequency profile for a single input BCR sequence (Figure 1). Some of these information sources
include substitution profiles for CFs in large, publicly available BCR sequence datasets and germline
gene sequence information. We combine the local context-specific profile information with global profile
information derived from other related germinal centers by regularizing the noisy local substitution profile
estimate and pooling it closer towards more robust global profile estimates. Even though each germinal
center focuses on binding to a unique epitope context, there are structural and possibly functional
properties associated with BCR sequences that are common across germinal centers that we can leverage.
In addition, our inference machinery uses both standard and spatial lasso penalties as model reg-
ularizers and, as a result, furnishes sparse, interpretable parameter estimates. While our output type
shares some similarities to that described by Sheng et al. (2017), the proposed objective, approach, and
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Figure 1: Amino acid substitution profiles viewed from three different perspectives: High-throughput se-
quencing data (HTS data) yields large amounts of VDJ sequences, but because of uneven sampling many
CFs will be sampled just once, resulting in poor representations of the amino acid substitution profiles
of those true CFs. “Substitution Profiles Using Related Families” (SPURF) is a statistical framework
that integrates large scale Rep-Seq data to predict amino acid substitution profiles for singleton CFs.
In vivo affinity maturation will test many different mutations and the resulting CFs reflect the amino
acid substitution profiles that we attempt to predict.
details differ (e.g. they predict substitution profiles for gene families, we predict substitution profiles for
CFs). We enable substitution profile prediction for single input BCR sequences based on profiles de-
rived from a high-quality repertoire dataset that contains B cell samples from many human donors. To
demonstrate the usefulness of our technique, we validate SPURF on an external dataset containing CFs
extracted from a single human donor. Lastly, we implement SPURF in an open-source software package
(https://github.com/krdav/SPURF), which outputs a predicted CF-specific substitution profile and an
associated logo plot based on a single input BCR sequence.
Methods
Overview
The aim of our model is to take a single sequence and predict the substitution profile for the CF from
which this single sequence derived. For this prediction problem, we have no direct information about
this desired substitution profile other than the information contained in the input sequence itself, but we
may use other information (e.g. from the inferred germline gene, simulated substitutions, or information
derived from published BCR sequence datasets). For large CFs, a CF-specific substitution profile can
be constructed simply by counting and making a per-site frequency matrix, with the rows of the matrix
representing each of the 20 amino acids, and the columns being the sequence positions.
For training, we extract a collection of such large CFs and use them to build “ground truth” CF-
specific substitution profiles as a training set for fitting the model. A randomly sampled single sequence
is then taken out from each of these large CFs to predict the substitution profile, which is compared to
the ground truth. We refer to these single sequences, sampled from large CFs, as subsamples.
To make the best possible prediction, we need a flexible model framework that can accommodate
different sources of information seamlessly (Figure 2). For example, previous work by Sheng et al.
(2016) and Kirik et al. (2017) suggests that the various V genes have different characteristic paths of
diversification. We can obtain a data-driven summary of that intuition by building profiles from large
Rep-Seq data sets stratified by V gene. We may also think that the neutral substitution process is an
important factor in determining substitution profiles (Sheng et al., 2016). We can quantify that sort of
information by repeatedly simulating the neutral substitution process using a context-sensitive model
3
(Cui et al., 2016).
To make predictions using these types of information, we need a way of describing the various sites,
and a way of integrating the information across the sites. We use the AHo numbering scheme (Honegger
and Plueckthun, 2001) to provide a single coordinate system to all sequences via its fixed-length num-
bering vector going from 1 to 149. Given this coordinate system, we use a site-wise weighted average of
the input predictive profiles using a α weight vector for each source of profile information.
To train this model, we fit the α vectors by minimizing some objective function that quantifies the
difference between the predicted profiles (where the prediction uses the subsampled sequence and the
external profile information) and the “ground truth” substitution profiles from the large CFs. Any
objective function could be used, but here we provide implementations of two such functions, a “fine-
grained” L2-error-based objective and a “coarse-grained” Jaccard-similarity-based objective (Jaccard,
1912).
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Figure 2: SPURF uses a per-site linear combination of substitution profiles from diverse sources to
predict complete substitution profiles from a single member of a CF. At the top are the different
profiles that serve as inputs to the model, some directly related to the naive sequence (X̂naiveAA
and X̂neut), and others partitions of the public Rep-Seq datasets (X̂vgene and X̂vsubgrp). To predict
a substitution profile, a weighted average is taken over the input sequence X and external profiles
X∗ =
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
(see the dashed line bubble). The vertical blue arrow indi-
cates that the weighted average (in the dashed line bubble) occurs at each of the 149 AHo positions.
Once a predicted profile is generated, this is compared to ground truth using either L2 error or Jaccard
similarity as a performance metric. The α vectors are estimated by optimizing the objective function,
which also includes a statistical regularization term to prevent overfitting (not shown for simplicity).
We use two forms of regularization to avoid overfitting the many parameters of this model. This in-
cludes a standard lasso penalty to shrink weights to zero that do not contribute significantly to prediction
performance (Tibshirani, 1996). We also use a fused lasso penalty (Tibshirani et al., 2005; Tibshirani,
2014) to smooth differences between parameters at nearby sites in the sequence. These regularization
terms have tuning parameters that regulate the strength of the penalties and are estimated using cross-
validation.
Given this setup, a forward stepwise selection procedure is run with cross-validation to pick the set
of external profiles to use in the final model. As a last check, this model is tested on an external dataset
to give a fair estimate of the prediction performance.
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Data
We divide input data into two parts, with each part for a respective purpose: 1) model fitting and model
testing and 2) providing “public” substitution profiles over clustered data to be used by our model.
Throughout this work, we are careful to not use the same data for both purposes as this would bias
our estimates; as a final validation, we test SPURF on an external dataset which is only used in this
validation. Because we do not model sequence error, we only include high-quality data that we have
high confidence in. We collect post-processed data files from 6 published works on Rep-Seq, which we
refer to as repertoire data 1 to 6 (RD1-6):
1. RD1 from Gupta et al. (2017), which is an Illumina MiSeq re-sequencing of the samples in Laserson
et al. (2014), where they sequence multiple time-points before and after influenza vaccination of 3
donors using the 454 pyrosequencing platform.
2. RD2 from Vander Heiden et al. (2017), from a study of the auto-immune disease Myasthenia Gravis
(MG), in which 9 MG patients and 4 healthy donors participate.
3. RD3 from Stern et al. (2014), containing data from different tissues in a study of B cell response
in 4 multiple sclerosis patients.
4. RD4 from Tsioris et al. (2015), from a study of neutralizing antibodies against the West Nile virus
by sequencing naive and memory cells from 7 virus infected donors.
5. RD5 from Shugay et al. (2014), from a study of Rep-Seq error correction by sequencing naive,
plasma, and memory cells from a single healthy donor.
6. RD6 from Meng et al. (2017), from the “B cell tissue atlas” acquired from the ImmuneDB web
portal.
All datasets are acquired in their post-processed form with read processing performed as described in
their respective publications.
The first five datasets (RD1-5) are prepared from unique molecular identifier (UMI) barcoded cDNA
spanning the whole VDJ region and sequenced on the Illumina MiSeq platform using overlapping paired-
end reads. Using the UMI, these reads are processed to address both PCR and sequencing errors giving
high confidence reads (Shugay et al., 2014). Briefly, UMIs are used for error correction in conjunction with
either of the pRESTO (Vander Heiden et al., 2014) or MIGEC (Shugay et al., 2014) processing pipelines
and an appropriate Phred quality score cutoff. Paired-end reads are assembled using pRESTO and only
the set of high confidence assembled reads constitute the final dataset used in this work. RD6 is the only
dataset not prepared with UMIs; however, it is sequenced directly from genomic DNA (gDNA) instead of
the more common practice of sequencing mRNA. Sequencing gDNA has the benefit of avoiding mutations
introduced by the transcription machinery as well as mutations introduced in the RT-PCR step. On the
other hand, DNA sequencing is not able to discriminate between expressed versus unexpressed BCRs (e.g.
in the case of faulty VDJ recombination) and therefore we apply aggressive filtering of non-functional
BCR sequences. We prefer quality over quantity and therefore avoid datasets from the 454 technology
because of their higher indel frequencies compared to those from Illumina technologies (Loman et al.,
2012).
Individual sequence files are merged based on donor identity so that the number of sample files
matches the number of donors; this process yields 33 donor files. The donor files are then annotated and
partitioned into CFs using the partis software (Ralph and Matsen IV, 2016a,b). Each donor file is run
separately from the other files so CFs are defined by their unique partis-inferred naive sequence and
donor identity. To ensure we obtain the highest quality and most biologically relevant sequences, partis
is run in its most restrictive mode, discarding all reads with VDJ recombinations that are deemed as
unproductive because of out-of-frame N/P junction nucleotides, missing invariant codons, or stop codons
inside the VDJ region; furthermore, the most accurate partis partitioning mode (“full”) is used to get
the best CF estimates. Lastly, productive VDJ-recombined sequences are removed if they contain indels
to assure concordance between the length of the naive sequence and the length of the read sequences in
its CF.
At this stage, some sequences contain ambiguous bases (e.g., because of primer masking); these are
allowed to pass only if the ambiguous bases are inside the first or last 30 nucleotides of the VDJ re-
gion (equivalent to the length of the potentially masked PCR primers), otherwise they are discarded.
This is a way of substituting the error-prone ends with neutral bases that minimize variance and main-
tain a conservative estimate of the substitutions; we also note that this has no apparent effect on the
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subsequently-described estimates (Figure 3 and Figure 4). For all sequences that pass this requirement,
ambiguous bases are substituted with bases from the naive sequence in batches of 3 nucleotides (i.e.
one codon) at a time until all ambiguous bases are resolved. Sequences are then translated into their
respective amino acid sequences and de-duplication of repeated amino acid sequences is done within each
CF. Because our statistical methodology operates on these amino acid sequences, we use the word “se-
quence” in subsequent sections to refer to these amino acid sequences. All CFs with fewer than 5 unique
sequences are discarded. From these remaining CFs, their inferred naive sequences are used for antibody
sequence numbering with the ANARCI software (Dunbar and Deane, 2015) under the AHo numbering
scheme (Honegger and Plueckthun, 2001). As a result of our restriction to non-indel sequences, all se-
quences within a given CF have equal length; thus, the AHo numbering from the naive sequence can
be positionally transferred to all its CF-related read sequences. Finally, for each CF, the amino acid
usage is extracted as a vector of counts at each AHo position. This overall dataset, which we call the
“aggregated” dataset, contains 518,174 sequences distributed over 31,893 CFs and is built as a matrix
of counts with rows denoting CFs and columns representing AHo positions and amino acid identities.
All data used to build this aggregated dataset is public and freely available. We provide processed data
partitioned into CFs upon request.
Model Fitting Dataset
To fit our CF-specific substitution profile prediction model, it is desirable to use the CFs from the
aggregated dataset with the most sequence members so we can train using the observed substitution
profiles with the least amount of noise; on the other hand, it is also desirable to extract CFs from as
many donors as possible to avoid overfitting towards a few similar donors. To achieve both goals, we pick
500 CFs as a “model fitting” dataset as follows. We first exclude any CFs with less than 100 sequences
from being eligible to be picked. We then cycle through donors, each time picking the largest remaining
eligible CF. If a donor does not have any remaining eligible CFs, it is skipped. The process ends when
500 CFs are found; all unpicked CFs are used as the “public” dataset.
In addition, we perform subsampling for each CF in the model fitting dataset; this is the information
from which we would like to predict the full profile. First, a single sequence is randomly chosen from
each CF, then partis is re-run using each of these subsampled sequences to re-do the VDJ annotation
and naive sequence inference. For some inferred naive DNA sequences, a stop codon is incidentally
present in the N/P nucleotides of the junction region; these are considered spurious and replaced by
the identically positioned codon from the input sequence. We stress that the CF-specific annotation
and naive sequence are inferred solely based on the subsampled sequence itself and are not determined
using information from the other CF sequence members. Additionally, the parameters used within the
partis clustering and annotation procedure are derived from an external dataset. Once we finish the
partis inference process on the subsampled sequences, we construct the amino acid count matrix for
these same sequences; we denote these substitution profiles as the “subsampled” profiles because they
are subsampled from the “full” profiles in the model fitting dataset.
Simulation of Neutral Substitution Profiles
For each of the 500 subsampled substitution profiles, we also simulate a neutral substitution profile via a
context-sensitive model. For each subsampled sequence, we calculate its number of somatic hypermuta-
tions (SHMs) and introduce that number of mutations sequentially into the inferred naive DNA sequence
according to the BCR-specific neutral substitution model S5F (Cui et al., 2016). Once the last mutation
is introduced, the simulated DNA sequence is translated into an amino acid sequence and stored as a
sample of the neutral substitution process. This procedure is repeated 10,000 times and the count profile
aggregated over all the samples is referred to as the “neutral” profile.
External Validation Dataset
For validation, a test set, called “Briggs”, is made from the healthy donor single cell droplet sequencing
dataset described in (Briggs et al., 2017). Briefly, the data is made by passing 3 million B cells into
6 emulsion pools, each droplet with a unique barcode, and then reverse transcribing mRNA inside
these droplets, attaching both a droplet and a molecular barcode. After breaking the emulsion, cDNA
is sequenced and processed using UMI consensus building using pRESTO. The highest-quality UMI
consensus sequence is extracted from each drop and aggregated into the final heavy chain dataset, which
is then further partitioned into CFs using partis. Finally, the validation dataset is built up in the same
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manner as the model fitting dataset, where the only difference is that we allow smaller CFs to enter
this dataset (minimum 28 sequences) in order to increase the number of extracted CFs to 100. For this
external dataset, sequences and processed data partitioned into CFs are available upon request.
Dataset summary statistics
Dataset Ndonors NCF Total Nseq Min Nseq Median Nseq Max Nseq
Aggregated 33 31,893 518,174 5 9 2,709
Model fitting 15 500 98,887 100 147 2,709
Public 33 31,393 419,287 5 8 104
Briggs 1 100 6,702 28 44 370
Table 1: Number of donors (Ndonors), number of CFs (NCF), number of sequences from all CFs (Total
Nseq), smallest CF size (Min Nseq), median CF size (Median Nseq), and maximum CF size (Max Nseq).
“Aggregated” is the base dataset aggregating RD1-6. “Model fitting” refers to the dataset with the 500
largest CFs from the “Aggregated” dataset. “Public” is the dataset left after the “Model fitting” dataset
is extracted from the “Aggregated” dataset. “Briggs” is the external validation dataset used for testing.
Input Data Tensor
Before we present our penalized tensor regression model, we first describe how the input data for the
model is constructed, building off the data descriptions in the last subsection. Throughout the rest of
this section, we assume the count matrices are normalized to frequencies and reorganized into three-
dimensional tensors (i.e. arrays) as follows. For any substitution profile tensor T = {Ti,j,k}, let Ti,j,k
denote the substitution frequency of the kth amino acid at the jth AHo position for the ith CF; we
represent the subsampled, full, and public substitution profile tensors as X, Y, and Z, respectively. Our
goal is to use the subsampled profiles X to predict the corresponding full substitution profiles Y (i.e. we
want to construct a function F (X) such that F (X) ≈ Y). We incorporate information from the public
dataset Z to enhance these predictions. In addition to the subsampled profiles, we use other types of
substitution profiles within F (X):
1. Public substitution profiles segmented by the inferred V-subgroup label (X̂vsubgrp);
2. Public substitution profiles segmented by the inferred V-gene label (X̂vgene);
3. Inferred naive sequence “substitution profiles” (X̂naiveAA);
4. Public substitution profiles segmented by the inferred naive sequence (X̂naiveAA-clust);
5. Public substitution profiles segmented by the original frequency profiles (X̂clust);
6. Neutral substitution profiles (X̂neut).
To compute the external profiles in X̂vsubgrp (resp. X̂vgene), we cluster the public dataset Z by averaging
its CF-specific substitution profiles according to the partis-inferred (Ralph and Matsen IV, 2016a)
IMGT defined (Lefranc, 2001) V-subgroup (resp. V-gene) labels and then assign each row in X to a
V-subgroup (resp. V-gene) cluster profile according to its V-subgroup (resp. V-gene) identity. We obtain
the second set of profiles X̂naiveAA by using the partis-inferred naive sequences as substitution profiles
(these profiles contain zeros and ones because they are based on one sequence only); we re-emphasize
that these naive sequences are inferred based only on the corresponding subsampled sequences in X.
We cluster the public dataset Z once more by running K-means clustering based on the inferred naive
sequences in Z and obtain our third set of substitution profiles X̂naiveAA-clust by assigning each CF in
X to its closest cluster centroid. The additional cluster profiles X̂clust are obtained similarly as above,
except in this case, we run K-means clustering based on the original frequency profiles in Z. The K-
means clustering procedure is run over a grid of cluster sizes ranging from 2 to 120 using the algorithm
described by Hartigan and Wong (1979) with the standard euclidean distance metric. Lastly, the tensor
X̂neut contains the simulated S5F neutral substitution profiles, which are described in the previous
subsection.
The frequency tensors X̂vsubgrp and X̂vgene are important to include in our analysis because these
profiles capture substitution information at the level of the V subgroup (V1, V2, ...) and V gene (V1-
5, V2-2, ...), respectively; this is similar to the types of profiles obtained in (Sheng et al., 2017). As
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described in the introduction, most germinal center lineages do not accumulate many mutations relative
to the naive sequence so substitution profiles based solely on the naive sequence (like X̂naiveAA) may be
informative for predicting the mutational patterns at conserved residue positions. In addition, we believe
that the X̂naiveAA-clust cluster profiles are useful as the naive sequence can greatly influence the pattern of
substitutions in a CF due to local sequence context. Unlike the X̂vsubgrp and X̂vgene substitution profiles,
which are based on IMGT labeling schemes, the profiles in X̂naiveAA-clust (and X̂clust) are determined by
a data-driven clustering procedure, which allows us to group CFs in Z in a more intricate fashion. The
simulated neutral substitution profiles X̂neut are able to provide some insight into the CF-specific SHM
processes without the corresponding clonal selection effects.
To condense our model presentation, we introduce a four-dimensional tensor X∗ that combines as
many of the input profiles mentioned previously as we would like, where p, the size of the fourth tensor
dimension, represents the number of external profiles used. We define X∗ ≡ {X∗i,j,k,l} to be the input
data tensor that incorporates all the external information we want to use in our substitution profile
predictions; note that i ∈ {1, ..., NCF } (NCF CFs in the tensors), j ∈ {1, ..., 149} (149 AHo positions),
k ∈ {1, ..., 20} (20 amino acids), and l ∈ {1, ..., p} (p external profiles). Each element X∗i,j,k,l represents
a substitution frequency as described above for Ti,j,k; for instance, X
∗
5,130,1,4 represents the substitution
frequency of the first amino acid (i.e. alanine) at the 130th AHo position for the 5th CF in the 4th
profile in the tensor. In addition, we use the indexing symbol • to extract all elements of a particular
array dimension of a tensor (i.e. X∗10,50,•,2 specifies the full substitution profile of the 20 amino acids at
the 50th AHo position for the 10th CF in the 2nd profile in the tensor). This setup allows us to easily
include as many external profiles as we would like.
Model Formulation
Given the subsampled profiles X and all the external profiles X∗, we compute a weighted average to form
an estimator of Y. Our independent-across-sites model F (X) =
[
f(X•,1,•), ..., f(X•,149,•)
]
is specified
as follows:
f(X•,j,•) ≡ f(X•,j,•;αj,•) =
p∑
l=1
αj,l ·X∗•,j,•,l +
(
1−
p∑
l=1
αj,l
)
·X•,j,•, (1)
where α = {αj,l}; 0 ≤ αj,l ≤ 1; 0 ≤
∑p
l=1 αj,l ≤ 1 represents the site-specific weights of the different
external profiles for j = 1, ..., 149 and l = 1, ..., p. Although we consider f to be a function of the per-site
data X•,j,•, the frequencies X∗•,j,•,l are computed using sequence-level, site-dependent information. With
149×p parameter values of α, this is a highly parameterized model so we include regularization terms to
prevent overfitting and obtain sparse, interpretable parameter estimates. Specifically, we use standard
and spatial (fused) lasso penalties to achieve these goals.
Standard lasso penalties shrink individual parameters to zero and are commonly used to obtain
sparse solutions in regression problems (Tibshirani, 1996). It has been shown that regression models
using standard lasso penalties provide more accurate predictions than models using best subset selection
penalties when there is a low signal-to-noise ratio (Hastie et al., 2017), which probably holds true in
our problem as well. In addition, standard lasso penalties are convex functions, which is important in a
regression problem as it guarantees that a local minimum is indeed a unique global solution (Boyd and
Vandenberghe, 2004).
On the other hand, fused lasso penalties shrink the differences between parameters to zero and are
useful in regression problems with spatially-related covariates (Tibshirani et al., 2005). We believe that
the α parameters have a spatial relationship (i.e. adjacent residues are under similar constraints); for
instance, given that the mutations in the framework regions are largely related to antibody stability, it
makes sense that we would weight external profile information similarly in those regions. The fusion
penalty in this setting enforces smoothness of the α trend across the AHo positions. For example, if
we penalize first-order differences of the α trend, the fitting procedure will necessarily favor trends that
have no slope (i.e. that are piecewise constant). We can obtain more flexible piecewise polynomial α
trends by penalizing higher-order successive differences of α (Tibshirani, 2014).
In our modeling framework, the standard lasso penalty is represented as
∑149
j=1
∑p
l=1 |αj,l| =
∣∣∣∣α∣∣∣∣
1
and the fused lasso penalty is specified by
∑p
l=1
∣∣∣∣∇d(α•,l)∣∣∣∣1, where || · ||q denotes the Lq norm and ∇d(·)
represents the dth difference operator. This ∇d(·) operator accepts a vector v as input (call its length nv)
and outputs a length-(nv−d) vector that results from successively differencing adjacent elements d times.
In the special case when d = 1, the fusion penalty becomes
∑p
l=1
∣∣∣∣∇1(α•,l)∣∣∣∣1 = ∑149j=2∑pl=1 |αj,l−αj−1,l|;
the |αj,l − αj−1,l| terms can be interpreted as first-order discrete derivatives.
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Our unpenalized objective function can be written as:
Lα2 ≡ Lα2 (Y, F (X)) =
1
149 ·NCF
149∑
j=1
∣∣∣∣Y•,j,• − f(X•,j,•;αj,•)∣∣∣∣22, (2)
where, as in the last subsection, NCF denotes the number of CFs in X and Y; we refer to this objective
as “L2 Error”. Our penalized estimation problem is defined in the following manner:
α̂ = argmin
α
Lα2 (Y, F (X)) + λ1
∣∣∣∣α∣∣∣∣
1
+ λ2
p∑
l=1
∣∣∣∣∇d(α•,l)∣∣∣∣1,
s.t. 0 ≤ αj,l ≤ 1, 0 ≤
p∑
l=1
αj,l ≤ 1, ∀j, l,
(3)
where λ1, λ2 ≥ 0 and d ∈ N signify tuning parameters. The differencing order d is used to specify a given
level of smoothness in the spatial α trend estimates because the
∑p
l=1
∣∣∣∣∇d(α•,l)∣∣∣∣1 term in the above
minimization problem encourages α trends that have dth order discrete derivatives close to 0 (i.e. that
are piecewise polynomials of order d−1). In addition, careful selection of λ1 and λ2 is required to obtain
an adequate model fit. Unfortunately, this is a constrained optimization problem with a multivariate
output and there are not any obvious ways to minimize such an objective without resorting to general-
purpose optimizers. Therefore, in all our experiments, we use the L-BFGS-B algorithm (Byrd et al.,
1995) to fit the above model.
Jaccard Similarity
While the model described above has computational and statistical appeal, in engineering applications it
is mostly interesting to know the high-frequency amino acid predictions; however, our penalized objective
function focuses attention on the complete substitution profiles and not exclusively the high-frequency
amino acids. To provide a metric more closely aligned with antibody engineering goals, we utilize the
Jaccard similarity metric, which can be used to measure differences between predicted and observed
high-frequency amino acid sets. Sets of high-frequency amino acids are defined at each position by a
minimum frequency cutoff t; Jaccard similarities are then computed between the observed and predicted
sets and averaged across each CF and AHo position in the dataset.
The Jaccard similarity metric (Jaccard, 1912) measures the similarity between two finite sets. Specif-
ically, for any sets A and B, the similarity metric J(A,B) is defined as the ratio of the intersection size
|A ∩ B| to the union size |A ∪ B|. It has these properties: 0 ≤ J(A,B) ≤ 1; J(A,B) = 1 when A = B
and J(A,B) = 0 when A ∩ B = ∅ (empty set). To formally establish our use of Jaccard similarity, we
define the following notation. Let Yi,j = {y ∈ Yi,j,• | y ≥ t} represent the set of amino acid frequencies
at AHo position j for CF i that has observed frequencies greater than or equal to the cutoff t and denote
Y ≡ {Yi,j} for i = 1, ..., NCF and j = 1, ..., 149. We define F̂Xi,j and F̂
X ≡ {F̂Xi,j} to be the analogous
quantities for the predicted amino acid frequencies. If we let A(Y ′) denote a function that accepts as
input an amino acid frequency set Y ′ (i.e. Yi,j or F̂Xi,j) and outputs the corresponding set of amino acid
identities, then our Jaccard similarity objective can be written as:
Jαt ≡ Jαt (Y, F (X)) =
1
149 ·NCF
NCF∑
i=1
149∑
j=1
J
(A(Yi,j),A(F̂Xi,j)), (4)
which is referred to as the “Jaccard Similarity” objective. We can define a penalized Jaccard estimation
problem by substituting −Jαt (Y, F (X)) for Lα2 (Y, F (X)) in Equation (3). Jaccard similarity optimiza-
tion is difficult using derivative-based optimization because of its discrete nature, so we use a smooth
approximation of the aforementioned metric for model fitting in our experiments (see Supplementary
subsection Smoothed Jaccard Similarity).
Forward Stepwise Selection
We devise a forward stepwise selection procedure to help us determine the combination of external
profiles that best predict the outcome of interest, which can be penalized L2 Error or Jaccard Similarity.
In this procedure, we initially try all possible external profiles in the model separately and determine
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the best fit using 5-fold cross-validation. We cache the best model from the initial step and continue
fitting models with two external profiles; the first external profile is fixed to be the best profile from the
previous round and the second profile can be any possible remaining external profile. We continue this
iterative scheme until we reach a prespecified limit on the number of external profiles allowed in X∗.
It is important to note that to ease computation, we perform forward selection using the unpenalized
variants of our models. Even though this procedure is greedy and not as thorough as all-subsets selection,
we believe this technique provides the best trade-off between accuracy and efficiency. We provide the
implementation of our stepwise procedures at https://github.com/krdav/SPURF.
Inference Pipeline
We apply a 80%/20% training/test split to the model fitting dataset described above. We first run the
forward stepwise selection procedure with a maximum profile limit of five to approximately determine
the best profile groupings starting with a single profile and ending with a group of five profiles. Using
the profile groupings from the previous step, we fit the penalized version of the model and use 5-fold
cross-validation to obtain estimates of the relevant tuning parameters, which consist of the lasso penalty
weights λ1, λ2 and the differencing order d; note that we report unpenalized performance estimates when
we run cross-validation. After we determine the optimal tuning parameters via cross-validation, we fit
the penalized model using the entire training portion of the model fitting dataset and the best tuning
parameters and cache the resulting parameter estimates of α. Once we obtain the estimates of α from
the penalized model, we can use them to compute the chosen performance metric on the testing portion
of the model fitting dataset and any other validation dataset of interest.
Results
As described in the methods (the Inference Pipeline subsection), we first need to infer the best profile
groupings to use in penalized model fitting. To determine these groupings, we run the forward stepwise
selection procedure for both the L2 error function and the smoothed Jaccard objective function with
a frequency cutoff t = 0.2 (Table 2). For both objective functions, the forward selection path is the
same until X∗ =
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
. For the L2 loss function, model performance is
the best when X∗ =
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
even though there are diminishing returns for
using profiles beyond X∗ =
{
X̂naiveAA, X̂vgene
}
. In a similar fashion, the Jaccard similarity estimates
tend to be highest when X∗ =
{
X̂naiveAA, X̂vgene
}
, despite the almost identical model performance
from just using X∗ =
{
X̂naiveAA
}
. For the subsequent penalized model fitting step, we choose to
evaluate the
{
X̂naiveAA, X̂vgene, X̂neut
}
and
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
profile groupings with
the L2 objective and
{
X̂naiveAA
}
and
{
X̂naiveAA, X̂vgene
}
with the smoothed Jaccard similarity objective.
Objective Function Unregularized CV
L2 Error
∅ X̂naiveAA X̂vgene X̂neut X̂vsubgrp X̂naiveAA-clust-5
0.110 0.0542 0.0459 0.0456 0.0455 0.0456
Jaccard Similarity ∅ X̂naiveAA X̂vgene X̂neut X̂vsubgrp X̂naiveAA-clust-85
(t = 0.2) 0.9170 0.9322 0.9324 0.9323 0.9319 0.9318
Table 2: Results of forward stepwise selection on our L2 and smooth Jaccard objective functions. The
performance estimates shown in the table are obtained using 5-fold cross-validation. Going from left
to right, each column represents the best profile addition into X∗ with the associated CV performance
estimate. For Jaccard, we fit using the smooth Jaccard objective, but report exact Jaccard similarity
estimates, both using frequency cutoff t = 0.2. Note that we fix the prespecified limit on the number of
external profiles allowed in X∗ to be 5. ∅ represents the model using only the input sequence.
We now use the approximate profile groupings obtained from the forward stepwise selection pro-
cedure to fit our regularized models. The penalized estimation problem has additional tuning pa-
rameters that must be determined. In our experiments, we cross-validate over penalty parameters;
λ1, λ2 = 10
−7, 5.05 × 10−6, 10−5; the differencing order, d = 1, 2, 3; and the two profile groupings
specified above for both the L2 error and Jaccard similarity objectives. The best regularized L2
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model uses X∗ =
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
, while the best regularized Jaccard model uti-
lizes X∗ =
{
X̂naiveAA
}
(Table S1). In summary, using many external profiles is important for predicting
the complete substitution profiles, while the inferred naive sequence is the only external profile deemed
useful for our model to accurately predict the observed high-frequency amino acids (where high-frequency
is defined by being at least 20% of the observed amino acids).
In addition to predictive performance, we are also interested in understanding how the estimated
parameter weights from our best regularized L2 model vary across the different external profiles in X
∗
and antibody regions. For convenience, we aggregate the estimates of α associated with the V gene
(X̂vgene and X̂vsubgrp) and with the full naive sequence (X̂naiveAA and X̂neut) as these sets of profiles
are intuitively similar (Figure 3); the V-gene and V-subgroup profiles are both derived by averaging over
different IMGT V germline gene labeling schemes and the simulated S5F neutral substitution profiles
originate from the CF-specific inferred naive sequence. Antibody heavy chain (and light chain) sequences
can be partitioned into framework regions (FWKs) and complementarity-determining regions (CDRs) by
the AHo definitions (Honegger and Plueckthun, 2001); the BCR binding affinity is largely determined by
the CDRs (especially by the heavy chain CDR3), while the FWKs encode the structural constraints of the
BCR and thus can be strongly conserved (Tomlinson et al., 1995). The X̂vgene and X̂vsubgrp profiles are
extremely important for prediction at FWK1-FWK3, which is not surprising as V germline genes extend
from the FWK1 to the beginning of the CDR3. In contrast, the X̂naiveAA and X̂neut external profiles
are heavily weighted in the CDR3 and FWK4; this result is also intuitive because the CDR3 is highly
variable across CFs as it is a strong determinant of antigen-binding specificity, the X̂naiveAA and X̂neut
profiles are our only CF-specific sources of external information, and the V gene specific profiles cannot
provide any information beyond the end of the V gene. Furthermore, the FWKs have, on average, more
support from the external profiles compared to the CDRs, which is consistent with our understanding
of antibody biochemistry as the FWKs are structurally constrained and thus need to be more conserved
compared to the more flexible CDRs. We note that the middle of the CDR3 has artificially low estimates
of α because most of the AHo positions in the CDR3 have only a few or no defined sequence positions
in the dataset (Figure S2).
Figure 3: A stacked barplot of the estimated parameter values of α from the best regularized L2 model.
For convenience, we aggregate the estimates of α associated with X̂vgene and X̂vsubgrp (blue) and with
X̂naiveAA and X̂neut (red). The black vertical lines represent the boundaries between the different CDRs
and FWKs.
While our penalized modeling framework allows for easy interpretation of the parameter estimates,
ultimately the quality of the α estimates is determined by their performance on independent test datasets.
Specifically, we compute the L2 error (L
α
2 ) and Jaccard similarity (J
α
0.2) between the predicted and
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observed profiles associated with both the testing portion of the model fitting dataset and the Briggs
validation dataset (Table 3); we remind readers that these predictions are made based on the subsampled
(i.e. single-sequence) profiles in the aforementioned datasets and compared to the corresponding actual
substitution profiles through the Lα2 and J
α
0.2 performance metrics (Figure 2). Our model improves upon
the “baseline” prediction performance, where “baseline” refers to predictions made using only the input
sequence (i.e. model predictions with all parameter values of α set to 0).
Objective Function Model Type Model fitting: test Briggs
L2 Error
Best 0.0492 0.0511
Baseline 0.114 0.129
Jaccard Similarity Best 0.9289 0.9227
(t = 0.2) Baseline 0.9156 0.9053
Table 3: The model performance results from predicting on independent datasets. We provide results
for both the testing portion of the model fitting dataset and the Briggs validation dataset. Note that the
term “baseline” refers to predictions made using only the input sequence (i.e. model predictions with all
parameter values of α set to 0).
In addition, we also want to know how well our model performs in the different antibody regions (i.e.
FWKs/CDRs). To answer this question, we compute the same metrics as shown in Table 3 for the differ-
ent FWKs and CDRs (Figure 4). To provide some insight into the variability of the model performance
estimates in the different regions, we calculate bootstrap standard errors, which are expressed as error
bars in Figure 4.
We see that our substitution profile prediction model performs well in the CDRs relative to the
baseline model. This is an important finding because antigen binding is largely determined by the
sequence segments in the CDRs, and especially CDR3. In fact, our models seem to provide the greatest
improvement in performance in the CDR3, which is also the hardest region to predict because it has the
highest amount of sequence variability. Another important takeaway is that the prediction performance
is better in FWKs than CDRs, which is presumably because FWKs have lower variance and are more
conserved compared to CDRs. In summary, our prediction models are able to systematically integrate
different data sources to make better predictions of the per-site amino acid compositions in CFs.
Our model also improves the prediction of the highest-frequency amino acid at a given position,
referred to here as the mode (Table 4). Indeed, the counts in the bottom-left cells (cases where the
model is correctly predicting the actual mode given an incorrect input sequence amino acid) are larger
than the counts in the top-right cells (vice-versa). In addition, the input sequence amino acids that
are not the true modes but correctly predicted by the model to be the actual modes are all germline
reversions, which is consistent with the X̂naiveAA profile being heavily weighted in our prediction model
(Figure 3). In the opposite case, where the input sequence amino acid is correct but the model prediction
is wrong, all the counts consist of germline predictions as well. In summary, many of the mode predictions
are just germline reversions and, in fact, most of these predictions are to the true modes (i.e. the actual
highest-frequency amino acids); however, most of the input sequence amino acids are the true modes
already (≈ 99%).
The in-sample and out-of-sample prediction performances demonstrate that our SPURF inference
pipeline is able to obtain accurate and robust estimates of α. Specifically, prediction performance is
consistently similar but slightly worse when comparing the Briggs dataset to the model fitting test set,
which likely reflects two things: 1) the median number of sequences per CF in the Briggs set is lower than
in the test set (Table 1) and 2) the model fitting dataset is sampled from the same donors as the dataset
for cross-validation. Regardless, the differences between the test and Briggs datasets are small, which
provides evidence in support of our model performance estimates. Subjective assessments of the inferred
substitution profiles coincide with our description of the L2 error metric, namely that fine-grained amino
acid substitution information is captured by SPURF (Figure S3).
The SPURF model setup produces interpretable and meaningful profile weights (Figure 5; per-profile
decomposition in Figure S4). The input sequence is strongly weighted in the CDRs, indicating that
substitutions in these regions are both specific and conserved within the CF and, therefore, cannot easily
utilize the information from other CFs. The weight on the V gene specific profiles spikes at CDR1 and at
the end of FWK3, which is at the heavy and light chain interface. We note that, as expected, the weight
on the V gene specific profiles is minimal downstream of FWK3 as this is the end of the V gene and the
beginning of the V-D junction region. As such, nothing prevents the V gene profiles from having a high
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Figure 4: The model performance results across the different antibody regions on the model fitting test
dataset and the Briggs validation dataset. In these plots, we compare the performances from our best
models to the baseline predictive performances using only the input sequence (i.e. model predictions with
all parameter values of α set to 0). The error bars show bootstrap standard errors.
Correct SPURF
germline |non-germline Mode Prediction?
Yes No
Is input amino Yes 10,473 | 465 156 | 0
acid the mode? No 349 | 0 170 | 395
(a) Model fitting: test dataset
Correct SPURF
germline | non-germline Mode Prediction?
Yes No
Is input amino Yes 10,541 | 376 178 | 1
acid the mode? No 474 | 0 196 | 393
(b) Briggs dataset
Table 4: Mode prediction results from both the testing portion of the model fitting dataset and the
Briggs dataset. For each CF and AHo position in a given dataset, we determine whether the predicted
mode (i.e. highest-frequency amino acid) from our best model is the same as the actual mode. Results
are aggregated based on whether or not the input sequence has the correct mode. At the left side of the
vertical bar (|) is the count for the germline predicted modes (i.e. situations when the predicted amino
acid mode is the naive sequence amino acid) and at the right side is the count for the non-germline
predicted modes (vice-versa).
weight downstream of FWK3, but the model framework has chosen these meaningful weights without
any manual interference. We ascribe this shrinkage feature of the weights to the standard lasso penalty
built into SPURF. The profiles that are derived from the inferred naive sequence (X̂naiveAA, X̂neut) take
up the missing weight of the V gene profiles as these are highly weighted in the CDR3 and FWK4.
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Figure 5: Positional profile weights α mapped to an antibody protein structure (PDB: 5X8L). The
antigen (PD-L1) appears as a purple surface at the top of the images, the light chain appears in white
cartoon, and the heavy chain is displayed using a blue to red color gradient; the grey dashed lines mark
the CDR loops. The color gradient represents the possible values of profile weights in α and goes from
blue at a zero weight to red at the maximum weight for the profile. The display in panels B and C is
rotated relative to panel A to better show results for CDR1 and CDR3; as a consequence, the CDR2
loop is hidden behind the CDR1. Panel A shows that the input sequence has high weight at the CDR1
and CDR2, panel B illustrates that the naive sequence and the neutral substitution profile have high
weight at the CDR3 and FWK4, and panel C demonstrates that the V gene and V subgroup profiles
are highly weighted in parts of the CDR1 but more generally in the FWKs, especially at the heavy and
light chain interface.
Discussion
In this paper, we present SPURF, a statistical framework for predicting CF-specific amino acid frequency
profiles from single input BCR sequences by leveraging multiple sources of external information. We use
standard and spatial lasso penalties to prevent our model from overfitting and obtain sparse, interpretable
estimates of the profile weights, expressed by an α matrix. The spatial lasso penalizes extreme differences
between spatially-adjacent profile weights, while the standard lasso penalties promote simpler models
by shrinking parameter values in α to 0 if the associated external profiles are not useful predictors. We
show that our method not only performs well on the held-out (test) portion of our model fitting dataset
but also provides accurate predictions on the Briggs external validation dataset. Indeed, we did not
obtain the Briggs validation dataset until after we ran our model inference pipeline on the model fitting
dataset.
Our work can be seen as a prediction-based extension of the work of Sheng et al. (2017) and Kirik
et al. (2017). This previous work illustrates that amino acid substitution profiles differ between germline
genes, a finding supported by the context specificity of somatic hypermutation (Cui et al., 2016). In our
work, we provide a prediction algorithm that takes a single BCR sequence from a clonal family as input
and outputs a CF-specific substitution profile estimate for the whole VDJ region.
We believe that this work will be a useful tool for antibody engineering in situations when it is
important to maintain antibody binding affinity to the same epitope. The predicted profiles from SPURF
can be used to choose the sites that are most tolerable for mutagenesis and the substitutions that are
most likely to maintain binding specificity; as such, this information can be used to engineer antibodies
with better biophysical properties.
To our knowledge, SPURF is the first prediction algorithm for B cell CF substitution profiles. There
are many possible extensions. In our SPURF inference pipeline, we subsample single BCR sequences
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from CFs to use as model input; unfortunately, this means that our modeling analysis is conditional
on a dataset that does not account for the variability associated with the subsampling process. One
obvious means of fixing the above problem is to draw multiple subsamples from each CF and treat these
multiple “observations” per CF within a dataset as a clustered data or weighted least squares problem. In
addition, our model fitting dataset consists of only the largest CFs because we need accurate CF-specific
substitution profile estimates to serve as the ground truth. This non-random sampling technique could
potentially bias our analysis results; however, this appears unlikely given our model’s performance on the
external Briggs validation dataset. Furthermore, our approach models per-site amino acid composition
in a CF and accounts for interactions between sites only through the fusion lasso penalties. It is well
known from other protein studies that spatially-adjacent amino acid residues evolve jointly (Jones et al.,
2011; Ekeberg et al., 2013), presumably to maintain structural stability, or in the case of antibodies to
stabilize the interface between heavy and light chains (Wang et al., 2009). In the context of antibodies,
residues in the FWKs have the potential to co-evolve (e.g. FWK residues flanking the CDRs could co-
evolve to stabilize the stem leading to the more flexible CDRs). Thus, figuring out how to incorporate
more detailed interaction effects in our model is an important avenue for future research.
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Supplementary Materials
Model Interpretation
In this subsection, we provide statistical motivation for our penalized regression model, which can be
interpreted as specifying an ensemble of multinomial logistic regression models at each AHo position.
We use some of the notation mentioned in the methods section and introduce new notation as needed.
We begin by describing the structure of the multinomial logistic regression models and then discuss how
we perform model averaging with these component models to form the estimator F (X) as stated in the
methods section. We conclude this subsection by showing that our regularized minimization problem
can be characterized as a maximum a posteriori (MAP) inference problem.
Suppose we observe M amino acids at the jth AHo position for the ith CF; for simplicity, we let
y1, ..., yM denote the observed amino acids. We assume that y1, ..., yM are drawn independently from a
common multinomial distribution with 20 possible categories and define a logistic regression model for
the substitution probabilities that does not include covariates. The standard way to formulate such a
model is as follows:
log
(
P(ym = c)
P(ym = 20)
)
= β(c), ∀c ∈ {1, ..., 20},
where c indexes a particular amino acid, β(20) ≡ 0, and m = 1, ...,M . We can equivalently represent the
model as:
P(ym = c) =
exp(β(c))∑20
c′=1 exp(β
(c′))
, ∀c ∈ {1, ..., 20},
where m = 1, ...,M . If we let p̂c denote the observed proportion of amino acid c in the sample, then it is
easy to show that maximizing the multinomial likelihood of the M observations with respect to the β(c)
parameters leads to the following parameter estimates:
β̂(c) = log
(
p̂c
p̂20
)
, ∀c ∈ {1, ..., 20},
which implies that:
P̂(ym = c) = p̂c, ∀c ∈ {1, ..., 20},
where P̂(ym = c) represents the logistic regression estimate of P(ym = c). Therefore, this multinomial
logistic regression model provides simple, intuitive estimates of the substitution probabilities. While
these logistic regression estimates may seem trivial, the underlying framework allows for easy integration
of CF-specific and site-specific information into our model.
The above model considers the substitution probabilities at only one AHo position so one could fit
this multinomial logistic regression model at each of the 149 AHo positions in a CF to obtain a complete
substitution profile estimate. In this paper, each CF-specific substitution profile estimate is a maximum
likelihood estimate (MLE) obtained by fitting 149 multinomial regression models to the observed amino
acid data in the CF. Given that our proposed modeling procedure computes a per-site weighted average
between the subsampled profiles X and all the external profile estimates X∗, one can interpret this model
F (X) as defining an ensemble of multinomial logistic regression estimates at each AHo position.
To specify this relationship more clearly, we denote the likelihood of Yi,j,• as follows:
Yi,j,• ∼ MVN
(
µi,j,•, σ
2I20
)
,
µi,j,• ≡
p∑
l=1
αj,l ·X∗i,j,•,l +
(
1−
p∑
l=1
αj,l
)
·Xi,j,•,
where MVN means multivariate normal, µi,j,• signifies the mean vector of Yi,j,• and defines our ensemble
model, σ2 represents an unknown variance parameter, I20 symbolizes the 20× 20 identity matrix, and p
represents the number of external profiles in X∗. Note that µi,j,• depends on the multinomial logistic
regression estimates described previously as both X and X∗ contain the MLE-based substitution profile
estimates. In addition, the form of µi,j,• relates to our previous definition of F (X) by observing that
µ•,j,• = f(X•,j,•;αj,•). We can also integrate the inequality constraints of the ensemble weights αj,l
into the likelihood function by including the indicator term 1α ≡ 1{0 ≤ αj,l ≤ 1; 0 ≤
∑p
l=1 αj,l ≤
1; ∀j, l}. The lasso penalties can be incorporated into our model through the use of sparsity-inducing
prior distributions.
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Specifically, the priors placed on α can be represented as:
P(α•,l) ∝ exp
(
−λ1
∣∣∣∣α•,l∣∣∣∣1 − λ2∣∣∣∣∇d(α•,l)∣∣∣∣1), ∀l ∈ {1, ..., p},
where λ1, λ2 ≥ 0 and d ∈ N are the same tuning parameters specified in the methods section (Park
and Casella, 2008; Kyung et al., 2010; Faulkner et al., 2018). These Laplace-like prior distributions can
be expressed as scale mixtures of normal distributions with independent gamma distributed variances
(Kyung et al., 2010); for a more comprehensive discussion on shrinkage priors of this form, we refer
readers to (Faulkner et al., 2018).
The posterior P(α|Y) can be presented in the following manner:
P(α|Y) ∝ P(Y|α)P(α)
∝
500∏
i=1
149∏
j=1
P(Yi,j,•|αj,•)
p∏
l=1
P(α•,l).
Note that we assume the Yi,j,• vectors are independent conditional on αj,• and the prior distribution on
α factorizes across l ∈ {1, ..., p}. The MAP estimate of the ensemble weights α is obtained by maximizing
P(α|Y) and is equivalent to the estimate that minimizes the regularized objective function shown in the
methods section. The latter assertion can be seen as the posterior on α can be monotonically transformed
into our penalized minimization problem (up to a constant factor in α).
Of course, there are limitations to this interpretation of our modeling framework. For instance, Yi,j,•
is a frequency vector, yet we model the likelihood of Yi,j,• using a multivariate normal distribution, which
has support over all real numbers; we could potentially remedy this problem by modeling the likelihood
of Yi,j,• as a Dirichlet distribution as its negative log-likelihood looks similar to a cross-entropy loss
function. In addition, we specify priors on α that also have support over the real line, which is not
realistic. Our assumption that the Yi,j,• vectors are conditionally independent given αj,• is used solely
for presentation purposes and does not hold in practice because the substitution profile data in both X
and X∗ are correlated across AHo positions. Despite these issues with our statistical representation of the
penalized regression model, our results demonstrate that the model is useful for predicting CF-specific
substitution profiles in data-sparse situations.
Smoothed Jaccard Similarity
As we stated in the methods section, optimization on the Jaccard similarity objective function is difficult
because this metric is locally flat with respect to our parameter values of α. For some small changes in
α, the averaged Jaccard similarity can remain at the same value because the Jaccard sets continue to
hold the same elements. This is a problem because the L-BFGS-B optimization algorithm uses gradient
information to determine its search direction for α and the Jaccard similarity gradients are often zero due
to the reasoning given above, which results in premature termination of the L-BFGS-B optimizer. We
now describe an approach to “smooth” the Jaccard similarity objective function that directly addresses
these concerns.
For notational simplicity, we let {ai}i=1:20 and {bi}i=1:20 denote the actual and predicted amino acid
frequencies, respectively, at a particular AHo position for a given CF. As before, t represents the cutoff
separating high versus low frequency amino acids. We also introduce the following indicator function
f(a, t) ≡ 1{a ≥ t} for any amino acid frequency a. If we further let A = A({ai | ai ≥ t}) and
B = A({bi | bi ≥ t}) with A(·) as defined in the methods section, then the Jaccard similarity between
sets A and B can be rewritten as:
J(A,B) ≡ |A ∩B||A ∪B| =
∑20
i=1 f(ai, t)f(bi, t)∑20
i=1 min
{
1, f(ai, t) + f(bi, t)
} .
The local flatness of the Jaccard similarity objective is due to the constant regions of f(ai, t) and the
non-smooth curvature of f(ai, t) at the jump point t. It turns out that f(ai, t) can also be described as
the limit of the following function:
f(ai, t) =
1
1 + e−(ai−t)
,
as  → ∞. Thus, to obtain a “smooth” transformation of J(A,B), we replace f(ai, t) with f(ai, t) in
the above equation of J(A,B) and set  (i.e. the steepness parameter) to be a small number. Figure S1
plots the function f(ai, 0.2) against ai ∈ [0, 1] for various values of .
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Figure S1: A plot of the function f(ai, 0.2) against ai ∈ [0, 1] for various values of . As  gets larger,
f(ai, 0.2) tends to the indicator function f(ai, 0.2).
Fortunately, the use of this “smooth” Jaccard similarity function allows the L-BFGS-B optimization
algorithm to converge properly. To use this “smoothed” objective function in the right manner, we
were interested in finding the largest values of  that still permitted proper L-BFGS-B convergence. We
utilized  = 23 throughout all our Jaccard similarity experiments because we found that this value of 
satisfied our selection criteria specified previously.
Supplementary Figures/Tables
Objective Function X̂∗ λ̂1 λ̂2 d̂ Regularized CV
L2 Error
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
10−7 10−5 3 0.0453
Jaccard Similarity {
X̂naiveAA
}
10−7 10−7 2 0.9316
(t = 0.2)
Table S1: The results from fitting the regularized models using 5-fold cross-validation. We present the
optimal tuning parameters selected from λ1, λ2 = 10
−7, 5.05 × 10−6, 10−5 and d = 1, 2, 3 and show the
associated cross-validated performance estimates. Note that the possible choices of X∗ for the L2 error
metric include the
{
X̂naiveAA, X̂vgene, X̂neut
}
and
{
X̂naiveAA, X̂vgene, X̂neut, X̂vsubgrp
}
groupings, while
the
{
X̂naiveAA
}
and
{
X̂naiveAA, X̂vgene
}
groupings are the possible X∗ choices for the smoothed Jaccard
similarity objective.
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Figure S2: A stacked barplot of the estimated parameter values of α from the best regularized L2
model. The black vertical lines represent the boundaries between the different CDRs and FWKs. Due
to the AHo antibody numbering used (Honegger and Plueckthun, 2001), some positions are assigned to
a gap character (an AHo position that does not map to a sequence position). The percentage of CFs
that are not assigned to gap characters is shown in the bottom plot for each AHo position. The input
sequence is heavily weighted in regions with high gap percentages because of the standard lasso penalty
included in our model. The conserved Tryptophan amino acid is observed as a spike in the X̂vgene and
X̂naiveAA profile weights following the end of CDR1 (position 43 in the AHo scheme). The conserved
Cysteine amino acid that defines the beginning of CDR3 is not readily observed, presumably because
this is invariant in all profiles. Generally, the input sequence has less weight in CDR3 and FWK4, which
indicates that there is some conservation during affinity maturation. Beyond CDR3 and FWK4, there is
a general trend that the input sequence has higher weight in the CDRs than in the FWKs, which suggests
that there is a higher level of conservation in the FWKs than in the CDRs during affinity maturation. A
more surprising observation is the spike in the X̂vgene, X̂vsubgrp, and X̂neut weights at AHo position 83
near the beginning of FWK3 (the “outer” loop); this could indicate a conserved position not previously
described.
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Figure S3: A logo plot displaying the input sequence, predicted profile, and true profile (ordered from top
to bottom) for an arbitrary CF in the Briggs dataset. The logos are plotted using AHo numbers (1-149)
and AHo positions undefined in the sequence are shown as empty columns. The predicted profile (middle)
captures much of the amino acid composition information associated with the full profile (bottom).
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Figure S4: Positional profile weights α mapped to an antibody protein structure (PDB: 5X8L). The
antigen (PD-L1) appears as a purple surface at the top of the images, the light chain appears in yellow
cartoon, and the heavy chain is displayed using a blue to red color gradient. The color gradient represents
the possible values of profile weights in α and goes from blue at a zero weight to red at the maximum
weight for the profile. The black dashed lines mark the CDR loops; note that the CDR2 loop is hidden
behind the CDR1. The colored balls represent the AHo-defined FWK/CDR boundaries. The black
arrows indicate regions of high profile weight. The X̂naiveAA profile is heavily weighted in CDR3 and
FWK4. The X̂vgene profile weighting is fairly even from FWK1 through FWK3; it spikes slightly in CDR1
and completely disappears beyond FWK3, which is expected as the V-D junction region starts past the
end of FWK3. The X̂neut profile weighting is fairly even across sites but spikes near the beginning of
FWK3 (the “outer” loop). The X̂vsubgrp profile weighting is distributed similarly to that of the X̂vgene
profile with the exception of a spike at the end of FWK3 (i.e. at the heavy and light chain interface).
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